Clinical Trial Information
| Clinical Trials Now Enrolling | Clinical Trial Designs |
| Download PDF | Download PDF |
 |
 |
Select ASH Presentations
View presentations during the event
Download PDF
Saturday, December 5th, 2020, 7:00 am – 3:30 pm
| Abstract #1230 Presenter: Michael Savona, MD Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) View abstract |
| Abstract #1037 Presenter: Amer Zeidan, MBBS, MHS Comparative Results of Azacitidine and Decitabine from a Large Prospective Phase 3 Study in Treatment Naive Patients with Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy. View abstract |
| Abstract #1056 Presenter: Christopher Hindley, PhD Anti-Tumor Activity of ASTX029, a Dual Mechanism Inhibitor of ERK1/2, in Preclinical AML Models View abstract |
| Abstract #1230 Presenter: Michael Savona, MD Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) View abstract Download presentation |
| Abstract #1037 Presenter: Amer Zeidan, MBBS, MHS Comparative Results of Azacitidine and Decitabine from a Large Prospective Phase 3 Study in Treatment Naive Patients with Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy. View abstract Download presentation |
| Abstract #1056 Presenter: Christopher Hindley, PhD Anti-Tumor Activity of ASTX029, a Dual Mechanism Inhibitor of ERK1/2, in Preclinical AML Models View abstract Download presentation |
Sunday, December 6th, 2020, 7:00 am – 3:30 pm
| Abstract #2409 Presenter: Betul Oran, MD Minimal Residual Disease Eradication with Guadecitabine (SGI-110) in the Post-Transplant Setting View abstract |
Monday, December 7th, 2020, 7:00 am – 3:30 pm
| Abstract #3328 Presenter: Betul Oran, MD, MS Maintenance Treatment with Guadecitabine (SGI-110) in High Risk MDS and AML Patients After Allogeneic Stem Cell Transplantation. View abstract |
| Abstract #3119 Presenter: Kiyomi Morita, MD, PhD Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) View abstract |
Except as stated, all compounds presented here are investigational, efficacy and safety have not been established. There is no guarantee that these agents will become commercially available.
Oral decitabine/cedazuridine (ASTX727) is approved in the U.S. for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia[CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. See full Prescribing Information